GlassScriptPhysician profile
Lica Mae Monobe
NPI 1679152904
$6,666.54
in general payments reported to CMS, 2019-2025
41 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $713 · 2023: $2,030 · 2024: $2,038 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,850 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,850.40 |
| Education | $103.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,065.63 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $700.53 | 2022-2025 | Jynarque, Rexulti, Voyxact |
| Abbvie INC. | $587.81 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $488.56 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Calliditas Therapeutics US INC. | $426.02 | 2023-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.06 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $304.19 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $277.35 | 2022-2025 | Jardiance, Mounjaro |
| Axsome Therapeutics, INC. | $229.16 | 2023-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $191.91 | 2024-2025 | Voquezna |
| Pfizer INC. | $180.03 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $165.33 | 2023-2024 | Velphoro |
| Novartis Pharmaceuticals Corporation | $162.61 | 2022-2024 | |
| Travere Therapeutics, INC. | $134.70 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.09 | 2022-2025 | Xifaxan, Trulance, Relistor |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $119.33 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $114.69 | 2022-2025 | Ozempic, Rybelsus |
| Inogen, INC. | $94.04 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Opko Pharmaceuticals, LLC | $89.60 | 2024-2025 | Rayaldee |
| Xeris Pharmaceuticals, INC. | $83.10 | 2022-2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.82 | 2023-2025 | Caplyta |
| Aurinia Pharma U.S., INC. | $68.51 | 2022-2023 | Lupkynis |
| Biohaven Pharmaceutical Holding Company LTD. | $66.91 | 2022 | |
| Nestle Healthcare Nutrition INC. | $58.37 | 2022-2023 | |
| Insulet Corporation | $52.63 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $50.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.01 | 2022-2023 | Aralast |
| Lundbeck LLC | $39.02 | 2025 | Rexulti |
| Bausch Health US, LLC | $38.07 | 2022-2023 | Aplenzin, Wellbutrin |
| Vifor Pharma, INC. | $33.71 | 2023 | Veltassa, Korsuva |
| Exact Sciences Corporation | $28.59 | 2024-2025 | Cologuard Collection Kit |
| Csl Behring | $25.46 | 2025 | Andembry |
| Amgen INC. | $24.94 | 2022 | |
| Tandem Diabetes Care, INC. | $24.29 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $23.44 | 2024 | Crysvita |
| Ascendis Pharma Endocrinology INC | $22.04 | 2025 | Yorvipath |
| Becton, Dickinson and Company | $20.21 | 2025 | Bd Max System, Bd Max Instrument |
| Radius Health, INC. | $20.12 | 2024 | Tymlos |
| Kyowa Kirin, INC. | $19.43 | 2024 | Crysvita |
| Corcept Therapeutics | $18.49 | 2024 | Korlym |
| Medtronic, INC. | $15.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lica Monobe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.